Although patients can switch safely and effectively from animal-derived semisynthetic human insulin to rh-insulin with no change in the expected dosage [3], global data suggest that the incidence of insulin-dependent DM may reach as high as ~9.5% [4] and that demand for insulin can be as high as 0.5–1 g/patient/year [5]. This evidence concerns the gene INS and substance dependence.